Clinical trial
A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
NCT00265135 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00265135 |
|---|---|
| Title | A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma |
| Official title | A Phase I/II Study of a Chimeric Antibody Against Interleukin-6 (CNTO 328) in Subjects With Metastatic Renal Cell Carcinoma |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | CNTO 328 |
| Enrollment | 68 |
| Start date | Aug 1, 2003 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Dec 14, 2005 |
| Last update posted | Jul 3, 2014 |
| Countries | Czechia, France, Netherlands, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: